This article was originally published in The Gray Sheet
Ongoing share repurchase program will be doubled from 25 mil. to 50 mil. shares, the firm reports April 6. A total of 21.2 mil. shares already have been bought back under the program, which was implemented in October 1987. "Current market conditions have created an excellent opportunity to strengthen the company through a purchase of its own shares," BMS Chairman and CEO Richard Gelb states in a same-day release.
You may also be interested in...
Approved in February as an on-demand remedy, Nurtec will be filed for migraine prevention after success in Phase III. It could be the first oral preventive therapy and first dual purpose migraine drug.
A protocol amendment is not needed to pause enrollment to decrease potential exposure to COVID-19, and virtual visits can be immediately implemented to ensure safety; experts say pandemic is forcing a rethinking in how companies carry out trials and in how regulators ensure patient safety and trial integrity.
South Korea’s Qurient achieves proof of concept in a Phase II study with its first-in-class antibiotic telacebec for tuberculosis and aims to file a US NDA for the orphan drug.